Outcomes and Trends

Outcomes data for hematopoietic cell transplants (bone marrow, PBSC, or cord blood transplants — BMT) available here include data on outcomes of autologous and allogeneic transplants collected by the Center for International Blood and Marrow Transplant Research (CIBMTR). Also available are CIBMTR data on trends in transplantation and data on unrelated donor and cord blood transplants from the National Marrow Donor Program (NMDP).

Analyses of NMDP transplants between 1987-2006 for all major diseases for which transplant is indicated have shown that in each disease category, survival has consistently, and sometimes dramatically, improved over time.

These analyses were published in the September 2008 supplement to Biology of Blood and Marrow Transplantation. [1] Additional transplant outcome curves from this supplement are available. See Improvements in Unrelated Donor Transplantation.

Transplant outcomes by disease
Figure 1. (CIBMTR data) View larger version	Probability of survival after HLA-identical sibling transplants for ALL, age <20 years, 1998-2006, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 2. (CIBMTR data) View larger version	Probability of survival after HLA-identical sibling transplants for ALL, age >20 years, 1998-2006, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 3. (NMDP data) View larger version	ALL: Survival of adult marrow transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Lymphoblastic Leukemia (ALL) — NMDP Transplant Outcomes.
Figure 4. (NMDP data) View larger version	ALL: Survival of pediatric marrow transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Lymphoblastic Leukemia (ALL) — NMDP Transplant Outcomes.
Figure 5. (NMDP data) View larger version	ALL: Survival of adult PBSC transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Lymphoblastic Leukemia (ALL) — NMDP Transplant Outcomes.
Figure 6. (CIBMTR data) View larger version	Probability of survival after HLA-identical sibling myeloablative transplants for AML, 1998-2006, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 7. (CIBMTR data) View larger version	Probability of survival after autotransplants for AML, age <20 years, 1998-2006, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 8. (CIBMTR data) View larger version	Probability of survival after autotransplants for AML, age >20 years, 1998-2006, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 9. (NMDP data) View larger version	AML: Survival of adult marrow transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Myelogenous Leukemia — NMDP Transplant Outcomes.
Figure 10. (NMDP data) View larger version	AML: Survival of pediatric marrow transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Myelogenous Leukemia — NMDP Transplant Outcomes.
Figure 11. (NMDP data) View larger version	AML: Survival of adult PBSC transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Myelogenous Leukemia — NMDP Transplant Outcomes.
Figure 12. (NMDP data) View larger version	AML: Survival of transplant patients >55 years old, myeloablative conditioning, PBSC and marrow, by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Acute Myelogenous Leukemia — NMDP Transplant Outcomes.
Figure 13. (NMDP data) View larger version	AML: Survival of transplant patients >55 years old, non-myeloablative conditioning, PBSC and marrow, by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Acute Myelogenous Leukemia — NMDP Transplant Outcomes.
Figure 14. (NMDP data) View larger version	Acute leukemias: Survival of pediatric cord blood transplant patients, all preparative regimens, by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006.
Figure 15. (CIBMTR data) View larger version	Probability of survival after transplants for CML in chronic phase, 1998-2006, by donor type and disease duration. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 16. (NMDP data) View larger version	CML: Survival of adult marrow myeloablative transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Chronic Myelogenous Leukemia (CML) — NMDP Transplant Outcomes.
Figure 17. (NMDP data) View larger version	CML: Survival of adult PBSC myeloablative transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Chronic Myelogenous Leukemia (CML) — NMDP Transplant Outcomes.
Figure 18. (CIBMTR data) View larger version	Probability of survival after autotransplants for Hodgkin disease, 1998-2006, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 19. (NMDP data) View larger version	Inherited immune system disorders: Overall survival of pediatric marrow transplant patients with severe combined immunodeficiency (SCID) and Wiskott-Aldrich syndrome (WAS), unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Immune Deficiencies and Metabolic Disorders — NMDP Transplant Outcomes.
Figure 20. (NMDP data) View larger version	Inherited metabolic disorders: Survival of pediatric marrow transplant patients with Hurler syndrome, adrenoleukodystrophy (ALD)/metachromatic dystrophy (MLD), unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Immune Deficiencies and Metabolic Disorders — NMDP Transplant Outcomes.
Figure 21. (NMDP data) View larger version	Non-malignant diseases: Survival of pediatric cord blood myeloablative transplant patients, unrelated donor transplants facilitated by the NMDP, 1998-2006. Diseases include histiocytic disorders, thalassemia major, severe combined immunodeficiency (SCID), inherited metabolic disorders, inherited platelet disorders, severe aplastic anemia, and Fanconi anemia.
Figure 22. (CIBMTR data) View larger version	Probability of survival after hematopoietic stem cell transplants for multiple myeloma, 1998-2006, by donor type. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 23. (CIBMTR data) View larger version	Probability of survival after allogeneic transplants for myelodysplastic syndromes (MDS) age <20 years, 1998-2006, by disease status and donor type. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 24. (CIBMTR data) View larger version	Probability of survival after allogeneic transplants for myelodysplastic syndromes (MDS) age >20 years, 1998-2006, by disease status and donor type. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 25. (NMDP data) View larger version	MDS: Survival of adult marrow myeloablative transplant patients by FAB classification, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Myelodysplastic Syndromes (MDS) — NMDP Transplant Outcomes.
Figure 26. (NMDP data) View larger version	MDS: Survival of adult PBSC myeloablative transplant patients by FAB classification, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Myelodysplastic Syndromes (MDS) — NMDP Transplant Outcomes.
Figure 27. (NMDP data) View larger version	MDS: Survival of adult marrow and PBSC transplant patients by age (18-54 yrs. or >55 yrs.), unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Myelodysplastic Syndromes (MDS) — NMDP Transplant Outcomes.
Figure 28. (NMDP data) View larger version	MDS RAEB/RAEB-T: Survival of adult PBSC and marrow transplant patients by conditioning regimen, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Myelodysplastic Syndromes (MDS) — NMDP Transplant Outcomes.
Figure 29. (CIBMTR data) View larger version	Probability of survival after autotransplants for diffuse large B-cell lymphoma, 2000-2006, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 30. (CIBMTR data) View larger version	Probability of survival after autotransplants for follicular lymphoma, 2000-2006, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 31. (CIBMTR data) View larger version	Probability of survival after HLA-identical sibling allotransplants for follicular lymphoma, 1998-2006, by disease status and conditioning regimen. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 32. (CIBMTR data) View larger version	Probability of survival after HLA-identical sibling allotransplants for diffuse large cell lymphoma, 1998-2006, by disease status and conditioning regimen. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
Figure 33. (NMDP data) View larger version	NHL: Survival of adult non-myeloablative transplant patients by cell source (PBSC or marrow), unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Non-Hodgkin's Lymphoma (NHL) — NMDP Transplant Outcomes.
Figure 34. (NMDP data) View larger version	Severe aplastic anemia: Survival of marrow transplant patients by age (adult or pediatric), unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Severe Aplastic Anemia & Fanconi Anemia — NMDP Transplant Outcomes.
Figure 35. (NMDP data) View larger version	Fanconi anemia: Survival of pediatric reduced-intensity marrow transplant patients, unrelated donor transplants facilitated by the NMDP, 1998-2006. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Severe Aplastic Anemia & Fanconi Anemia — NMDP Transplant Outcomes.
Diseases treated with transplant
Figure 36. (CIBMTR data) View larger version	Indications for hematopoietic stem cell transplantation in North America, 2005. For discussion of these data, see Diseases Treatable by Hematopoietic Cell Transplant.
Figure 37. (CIBMTR data) View larger version	Indications for allogeneic hematopoietic stem cell transplantation, worldwide, 2005. For discussion of these data, see Diseases Treatable by Hematopoietic Cell Transplant.
Number of transplants facilitated by the NMDP
Figure 38. (NMDP data) View larger version	NMDP transplants by cell source, adult recipients, 1988-2009. (NMDP data is fiscal year data through September 30, 2009) For discussion of these data, see Trends in Allogeneic Transplants.
Figure 39. (NMDP data) View larger version	NMDP transplants by cell source, pediatric recipients, 1988-2009. For discussion of these data, see Trends in Allogeneic Transplants.
Figure 40. (NMDP data) View larger version	NMDP transplants by patient diagnosis, malignant diseases, 1999-2009.
Figure 41. (NMDP data) View larger version	NMDP transplants by patient diagnosis, non-malignant diseases, 1999-2009.
Figure 42. (NMDP data) View larger version	NMDP transplants by patient age and year, 1998-2009.
Sources of cells for transplant
Figure 43. (CIBMTR data) View larger version	Autologous stem cell sources by recipient age, 1997-2006. For discussion of these data, see Hematopoietic Cell Sources Tailored to the Patient.
Figure 44. (CIBMTR data) View larger version	Allogeneic stem cell sources by recipient age, 1997-2006. For discussion of these data, see Hematopoietic Cell Sources Tailored to the Patient.
References Weisdorf D, (Ed.). The National Marrow Donor Program reports to the community on 20 years of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14(9, Suppl. 3):1-60. http://www.bbmt.org/issues/contents?issue_key=S1083-8791(08)X0009-6